The company - Agreements related to avdoralimab with Novo Nordisk and with AstraZeneca (Details) € in Millions |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
|
Jan. 01, 2018
trial_cohort
partners
|
Jul. 31, 2017
EUR (€)
|
Dec. 31, 2020
EUR (€)
|
|
| 2017 Avdoralimab In-Licensing Agreement With Novo Nordisk A/S | |||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
| Upfront payment | € 40.0 | ||
| Upfront payment, shares issued | 37.2 | ||
| Upfront payment, cash | 2.8 | ||
| Payments for milestone | € 1.0 | ||
| Maximum payments to counter party upon achievement of certain milestones | € 369.0 | ||
| 2018 Avdoralimab AstraZeneca Agreement | |||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
| Sponsor of trial | partners | 2 | ||
| Number of cohorts of the trial that did not meet primary endpoints | trial_cohort | 2 |